ReviewPharmaceuticals (Basel, Switzerland)2025

Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment.

Rui Salvador et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.